Based on the promising results obtained in our preclinical studies, we performed a clinical feasibility study in patients with metastatic melanoma to determine the biodistribution and tracer kinetics of [18F]FB-IL2, and to evaluate whether serial [18F]FB-IL2 PET imaging can detect an ICI-induced immune response in tumor lesions. This evidence concerns the gene IL2 and metastatic melanoma.